drugset / Trial / NCT00361595

Intervenous (IV) Zoledronic Acid After Forteo in Postmenopausal Women

NCT00361595

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the adequacy of zoledronic acid in maintaining bone mass after two years of treatment with Forteo, in postmenopausal women.

Timeline

Start
2006-08
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Zoledronic acid Other / unclassified 5 mg Intravenous

Indications